Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Randomised, Double-blind, Placebo Controlled Phase II Clinical Study of Chiglitazar in Patients With Nonalcoholic Steatohepatitis Accompanied by Elevated Triglycerides and Insulin Resistance

NCT05193916 is registered in ClinicalTrials.gov with Chipscreen Biosciences, Ltd. as lead sponsor.

NCT NCT05193916
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05193916 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Randomised, Double-blind, Placebo Controlled Phase II Clinical Study of Chiglitazar in Patients With Nonalcoholic Steatohepatitis Accompanied by Elevated Triglycerides and Insulin Resistance
Lead sponsor
Chipscreen Biosciences, Ltd.
Phase
Phase 2
Overall status
Completed
Start date
March 21, 2022
Completion date
January 2, 2024
Enrollment
104 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

nash